Experimental analysis demonstrated improved chemotherapy outcomes with PTCH1 inhibition in triple-negative breast cancer, suggesting new treatment strategies.
Key Points
Inhibition of PTCH1 significantly increased the cytotoxic effects of chemotherapy agents like doxorubicin and docetaxel in triple-negative breast cancer cell lines.
PTCH1 has been identified as a multidrug transporter that plays a crucial role in the resistance of TNBC to chemotherapy treatments.
The study involved testing PTCH1 inhibition on three different triple-negative breast cancer cell lines, revealing enhanced effectiveness and reduced cell migration.
Targeting PTCH1's drug efflux activity has potential implications for improving treatment protocols for patients with triple-negative breast cancer.